Nvidia Dumped Recursion Pharmaceuticals Stock. Should You?

Core Viewpoint - NVIDIA Corporation has completely exited its position in Recursion Pharmaceuticals, which has led to mixed reactions in the market, with some investors seeing opportunity while others reacted negatively to the news [1][2][3]. Group 1: NVIDIA's Actions - NVIDIA held 7.71 million shares of Recursion Pharmaceuticals at the end of Q3 2025, which was a small part of its AI portfolio [2]. - Following the disclosure of its exit, NVIDIA's stock experienced a drop of up to 14% during the trading session, but later recovered to close nearly 2% higher [2]. Group 2: Market Reactions - Despite NVIDIA's exit, ARK Invest, led by Cathie Wood, purchased 1.25 million shares of Recursion across two ETFs, indicating a contrasting investment strategy [3]. - The market has shown little patience with Recursion Pharmaceuticals, as its stock has fallen 66.1% over the past 52 weeks and 27.6% over the last six months [6]. Group 3: Recursion Pharmaceuticals Overview - Recursion Pharmaceuticals is a clinical-stage biotechnology company focused on drug discovery, with a market capitalization of approximately $1.8 billion [5]. - The company reported Q3 fiscal 2025 results showing revenue of $5.2 million, which represents an 80.2% year-over-year decline and is significantly below analyst expectations of $16.98 million [9]. Group 4: Valuation Insights - Recursion's stock is currently trading at 29.82 times sales, which is above the industry average, indicating a premium valuation [8].